88 related articles for article (PubMed ID: 20386017)
1. Sotrastaurin and tacrolimus coadministration: effects on pharmacokinetics and biomarker responses.
Kovarik JM; Stitah S; Slade A; Vitaliti A; Straube F; Grenet O; Winter S; Sfikas N; Seiberling M
J Clin Pharmacol; 2010 Nov; 50(11):1260-6. PubMed ID: 20386017
[TBL] [Abstract][Full Text] [Related]
2. Overview of sotrastaurin clinical pharmacokinetics.
Kovarik JM; Slade A
Ther Drug Monit; 2010 Oct; 32(5):540-3. PubMed ID: 20683390
[TBL] [Abstract][Full Text] [Related]
3. Sotrastaurin and cyclosporine drug interaction study in healthy subjects.
Kovarik JM; Stitah S; Slade A; Vitaliti A; Straube F; Grenet O; Winter S; Sfikas N; Seiberling M
Biopharm Drug Dispos; 2010 Jul; 31(5-6):331-9. PubMed ID: 20578209
[TBL] [Abstract][Full Text] [Related]
4. Sotrastaurin single-dose pharmacokinetics in de novo liver transplant recipients.
Kovarik JM; Neuhaus P; Cillo U; Weber M; Stitah S; Gatlik E; Meiser K; Slade A
Transpl Int; 2011 Mar; 24(3):276-83. PubMed ID: 21134243
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients.
Kovarik JM; Steiger JU; Grinyo JM; Rostaing L; Arns W; Dantal J; Proot P; Budde K;
Transplantation; 2011 Feb; 91(3):317-22. PubMed ID: 21157403
[TBL] [Abstract][Full Text] [Related]
6. Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration.
Kovarik JM; Bartlett M; Rordorf C; Antunes MC; Winter S; Marbach P; van Marle S
Int J Clin Pharmacol Ther; 2010 Feb; 48(2):103-8. PubMed ID: 20137762
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation.
Matz M; Naik M; Mashreghi MF; Glander P; Neumayer HH; Budde K
Expert Opin Drug Metab Toxicol; 2011 Jan; 7(1):103-13. PubMed ID: 21142580
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effects of Isatis tinctoria L. and tacrolimus in the prevention of acute heart rejection in mice.
Wang Y; Qin Q; Chen J; Kuang X; Xia J; Xie B; Wang F; Liang H; Qi Z
Transpl Immunol; 2009 Dec; 22(1-2):5-11. PubMed ID: 19766187
[TBL] [Abstract][Full Text] [Related]
9. The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation.
Evenou JP; Wagner J; Zenke G; Brinkmann V; Wagner K; Kovarik J; Welzenbach KA; Weitz-Schmidt G; Guntermann C; Towbin H; Cottens S; Kaminski S; Letschka T; Lutz-Nicoladoni C; Gruber T; Hermann-Kleiter N; Thuille N; Baier G
J Pharmacol Exp Ther; 2009 Sep; 330(3):792-801. PubMed ID: 19491325
[TBL] [Abstract][Full Text] [Related]
10. Sotrastaurin, a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis.
Manicassamy S
Curr Opin Investig Drugs; 2009 Nov; 10(11):1225-35. PubMed ID: 19876790
[TBL] [Abstract][Full Text] [Related]
11. The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole.
Kovarik JM; Huang HL; Slade A; Sfikas N; Chandler PA
Br J Clin Pharmacol; 2009 Sep; 68(3):381-5. PubMed ID: 19740395
[TBL] [Abstract][Full Text] [Related]
12. Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720.
Weckbecker G; Pally C; Beerli C; Burkhart C; Wieczorek G; Metzler B; Morris RE; Wagner J; Bruns C
Transpl Int; 2010 May; 23(5):543-52. PubMed ID: 20003043
[TBL] [Abstract][Full Text] [Related]
13. Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans.
Böhler T; Nolting J; Kamar N; Gurragchaa P; Reisener K; Glander P; Neumayer HH; Budde K; Klupp J
Ther Drug Monit; 2007 Feb; 29(1):77-86. PubMed ID: 17304154
[TBL] [Abstract][Full Text] [Related]
14. Cytokines correlate with age in healthy volunteers, dialysis patients and kidney-transplant patients.
Böhler T; Canivet C; Nguyen PN; Galvani S; Thomsen M; Durand D; Salvayre R; Negre-Salvayre A; Rostaing L; Kamar N
Cytokine; 2009 Mar; 45(3):169-73. PubMed ID: 19147373
[TBL] [Abstract][Full Text] [Related]
15. Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers.
Hebert MF; Park JM; Chen YL; Akhtar S; Larson AM
J Clin Pharmacol; 2004 Jan; 44(1):89-94. PubMed ID: 14681346
[TBL] [Abstract][Full Text] [Related]
16. A randomized, open-label, two-period, crossover bioavailability study of two oral formulations of tacrolimus in healthy Korean adults.
Park K; Kim YS; Kwon KI; Park MS; Lee YJ; Kim KH
Clin Ther; 2007 Jan; 29(1):154-62. PubMed ID: 17379055
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship and pharmacokinetic studies of sotrastaurin (AEB071), a promising novel medicine for prevention of graft rejection and treatment of psoriasis.
Wagner J; von Matt P; Faller B; Cooke NG; Albert R; Sedrani R; Wiegand H; Jean C; Beerli C; Weckbecker G; Evenou JP; Zenke G; Cottens S
J Med Chem; 2011 Sep; 54(17):6028-39. PubMed ID: 21797275
[TBL] [Abstract][Full Text] [Related]
18. Effects of the new immunosuppressive agent AEB071 on human immune cells.
Matz M; Weber U; Mashreghi MF; Lorkowski C; Ladhoff J; Kramer S; Neumayer HH; Budde K
Nephrol Dial Transplant; 2010 Jul; 25(7):2159-67. PubMed ID: 20100729
[TBL] [Abstract][Full Text] [Related]
19. Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients.
Kuypers DR; Vanrenterghem Y
Clin Ther; 2004 Nov; 26(11):1834-44. PubMed ID: 15639695
[TBL] [Abstract][Full Text] [Related]
20. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
Pascual J; del Castillo D; Cabello M; Pallardó L; Grinyó JM; Fernández AM; Brunet M
Transplantation; 2010 Apr; 89(8):994-1000. PubMed ID: 20335831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
